Interaction of hemopexin, albumin and liver fatty acid‐binding protein with protoporphyrin

Elizabeth Knobler, Maureen B. Poh‐Fitzpatrick, Donna Kravetz, William R. Vincent, Ursula Muller‐Eberhard, Styliani H. Vicent – 1 December 1989 – Equilibrium constants for the binding of protoporphyrin to serum albumin and hemopexin and liver cytosolic fatty acid‐binding protein of the rat were determined fluorometrically. The experimental equilibrium constant [106M−1 (mean ± S. D.)] values were 8.4 ± 1.3, 10.0 ± 2.4 and 34.0 ± 3.0 for albumin, hemopexin and liver fatty acid‐binding protein, respectively.

Pharmacokinetics of benzodiazepine antagonist Ro 15–1788 in cirrhotic patients with moderate or severe liver dysfunction

Gilles Pomier‐Layrargues, J.‐François Giguère, Joël Lavoie, Bernard Willems, Roger F. Butterworth – 1 December 1989 – Ro 15–1788, a benzodiazepine antagonist, has been advocated as a new treatment for hepatic encephalopathy. This drug is extensively metabolized by the liver in normal subjects. In the present study, we examined Ro 15–1788 disposition in eight healthy controls (Group I), eight cirrhotic patients with moderately impaired liver function (Pugh score >10, Group II) and eight patients with severe liver dysfunction (Pugh score > 10, Group III).

Tumor necrosis factor‐α induces a kB sequence‐specific DNA‐binding protein in human hepatoblastoma HepG2 cells

Ranjit Banerjee, Saul Karpen, Miriam Siekevitz, Gabriella Lengyel, Joachim Bauer, George Acs – 1 December 1989 – Tumor necrosis factor‐α is an inducer of acute‐phase protein synthesis in liver cells. The mechanism by which tumor necrosis factor‐α alters gene expression in these cells is largely unknown. In this study, we demonstrate that tumor necrosis factor‐α stimulates human immunodeficiency virus‐1 long terminal repeat‐promoted gene expression in the human hepatoblastoma HepG2 cell line and increased binding of trans‐activating factors to kappa B (kB) DNA sequences.

Hepatic drug clearance in chronic liver disease: Can we expect to find a universal, quantitative marker of hepatic function?

Denis J. Morgan, Richard A. Smallwood – 1 November 1989 – Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases. Galactose blood clearance, which may be taken as effective hepatic blood flow, decreased by approximately 30% in patients with cirrhosis (12.49 ± 0.76 ml/min/kg; mean ± SE; n = 17) compared with normal subjects (18.17 ± 1.03 ml/min/kg; n = 5).

Reduced‐size orthotopic liver transplantation: Use in the management of children with chronic liver disease

Jean C. Emond, Peter F. Whitington, J. Richard Thistlethwaite, Estella M. Alonso, Christoph E. Broelsch – 1 November 1989 – Reducing the size of a liver for use in a recipient smaller than the donor is one way to reduce mortality before orthotopic liver transplantation in children because of the scarcity of pediatric organ donors. In this report, we review the results of this approach over the past 2 years, during which we have used reduced‐size orthotopic liver transplantation routinely in small children.

Tissue‐specific activity of heterologous viral promoters in primary rat hepatocytes and Hep G2 cells

Fang Xian‐Jun, Armand Keating, Jean de Villiers, Morris Sherman – 1 November 1989 – In preparation for studies using gene transfer, we have identified transcriptional control elements which are active in primary rat hepatocytes. We used plasmids which were constructed so that the promoter or enhancer of interest initiated transcription of the bacterial chloramphenicol acetyltransferase (CAT) gene.

Subscribe to